Sandoz Group AG (SDZ)
Quick facts
| Ticker | SDZ (SIX) |
|---|
Marketed products
- HYRIMOZ · Other
- ENZEEVU · Other
- JUBBONTI · Other
- Dopaminergic Agonists · Neurology
Dopaminergic agonists activate dopamine receptors in the brain to increase dopamine signaling. - Duragesic · Other
- Generic tacrolimus
- HX575 recombinant human erythropoietin alfa
- Interleukin-3 · Hematology/Oncology
Interleukin-3 is a cytokine that stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells, promoting the production of multiple blood cell lineages. - MabThera · Oncology, Immunology
MabThera (rituximab) is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. - TYRUKO · Other
- Omnitrope · Other
- Opana · Other
- ZIEXTENZO · Other
- CIMERLI · Other
Phase 3 pipeline
- Adalimumab - GP2017 · Immunology
GP2017 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. - Adalimumab - US licensed Humira · Immunology
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. - Angal, lozenges [menthol], · Respiratory/Otolaryngology
Menthol provides local anesthetic and cooling sensations to soothe throat irritation and cough. - Angal S, topical spray [Menthol] · Pain Management
Menthol produces a cooling sensation by activating TRPM8 cold-sensitive receptors on nerve endings, providing topical analgesic and anti-inflammatory relief. - ANTI-ANGIN® FORMULA · Cardiovascular
Anti-Angin® Formula reduces anginal symptoms through a combination of vasodilatory and anti-ischemic agents that improve coronary blood flow and reduce cardiac workload. - ANTI-ANGIN® FORMULA, topical metered spray · Otolaryngology / Pain Management
ANTI-ANGIN® FORMULA provides topical anesthetic and anti-inflammatory relief for sore throat and oral pain through local numbing and soothing agents. - Broncho-munal®
- CYB704 · Immunology
CYB704 is a selective inhibitor of complement factor D that reduces complement cascade activation and downstream inflammatory responses. - EP2006 · Hematology/Oncology
EP2006 is a biosimilar of epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. - ERYPO®, Janssen-Cilag · Hematology
ERYPO® (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production. - GME751 · Unknown
GME751 is a small molecule drug that targets the molecular target. - GP2013
- GP2013 - A Proposed biosimilar rituximab · Immunology, Oncology
GP2013 is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity. - GP2015 · Oncology
GP2015 is a biosimilar of pegfilgrastim that stimulates neutrophil production by binding to G-CSF receptors on bone marrow progenitor cells. - GP2015 Etanercept · Immunology
GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage. - GP2017 Adalimumab · Immunology
GP2017 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated disease activity. - GP2411 · Oncology
GP2411 is a biosimilar of filgrastim that stimulates the production and release of neutrophils from bone marrow to support immune function. - HX575 epoetin alfa · Hematology / Oncology
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. - HX575 epoetin alfa Hexal AG · Hematology/Oncology
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. - HX575 epoetin alfa (Sandoz) · Hematology / Oncology
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. - Keytruda-EU · Oncology
Keytruda (pembrolizumab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells. - LA-EP2006 · Hematology
LA-EP2006 is a long-acting recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to and activating the erythropoietin receptor. - LRG-002 · Oncology
LRG-002 is a monoclonal antibody that targets the PD-1 receptor. - Ocrevus-EU · Immunology/Neurology
Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis. - Ocrevus-US · Immunology
Ocrevus-US is a monoclonal antibody that targets CD20 on B cells. - Originator rituximab - Rituxan ® or MabThera ® · Oncology, Immunology
Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. - SOK583A1 · Oncology
SOK583A1 is a small molecule drug that targets the molecular target. - US-licensed epoetin alfa · Oncology, Nephrology
Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: